BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 241 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,635,841 | -17.6% | 231,051 | -18.1% | 0.00% | 0.0% |
| Q2 2023 | $1,985,400 | -8.8% | 282,017 | +8.0% | 0.00% | 0.0% |
| Q1 2023 | $2,177,015 | -24.8% | 261,033 | +3.5% | 0.00% | -33.3% |
| Q4 2022 | $2,895,841 | -7.9% | 252,251 | +1.1% | 0.00% | -25.0% |
| Q3 2022 | $3,144,000 | +20.4% | 249,508 | +1.0% | 0.00% | +33.3% |
| Q2 2022 | $2,612,000 | -37.7% | 246,938 | -4.2% | 0.00% | -25.0% |
| Q1 2022 | $4,191,000 | +24.1% | 257,789 | +5.7% | 0.00% | +100.0% |
| Q4 2021 | $3,378,000 | -68.5% | 243,908 | -67.4% | 0.00% | -66.7% |
| Q3 2021 | $10,736,000 | -5.2% | 747,045 | +4.3% | 0.01% | 0.0% |
| Q2 2021 | $11,320,000 | +371.7% | 716,029 | +203.3% | 0.01% | +500.0% |
| Q1 2021 | $2,400,000 | -20.6% | 236,047 | -41.8% | 0.00% | 0.0% |
| Q4 2020 | $3,023,000 | -31.3% | 405,766 | -68.4% | 0.00% | -66.7% |
| Q3 2020 | $4,403,000 | +20.5% | 1,282,146 | +67.1% | 0.00% | 0.0% |
| Q2 2020 | $3,655,000 | +109.0% | 767,087 | -12.3% | 0.00% | +50.0% |
| Q1 2020 | $1,749,000 | -68.4% | 874,391 | -45.4% | 0.00% | -50.0% |
| Q4 2019 | $5,527,000 | +64.7% | 1,602,315 | +36.8% | 0.00% | +33.3% |
| Q3 2019 | $3,356,000 | +499.3% | 1,171,439 | +691.1% | 0.00% | – |
| Q2 2019 | $560,000 | -59.7% | 148,076 | -13.4% | 0.00% | -100.0% |
| Q1 2019 | $1,391,000 | +73.0% | 170,957 | +71.7% | 0.00% | 0.0% |
| Q4 2018 | $804,000 | +171.6% | 99,595 | +156.7% | 0.00% | – |
| Q3 2018 | $296,000 | -17.3% | 38,795 | -37.8% | 0.00% | – |
| Q2 2018 | $358,000 | -12.9% | 62,417 | -27.4% | 0.00% | – |
| Q1 2018 | $411,000 | +20.2% | 86,014 | +23.6% | 0.00% | – |
| Q4 2017 | $342,000 | -32.3% | 69,570 | -27.7% | 0.00% | – |
| Q3 2017 | $505,000 | -14.4% | 96,247 | -9.5% | 0.00% | -100.0% |
| Q2 2017 | $590,000 | -36.6% | 106,318 | -4.1% | 0.00% | 0.0% |
| Q1 2017 | $931,000 | +127.6% | 110,837 | +71.5% | 0.00% | – |
| Q4 2016 | $409,000 | -16.9% | 64,633 | -42.0% | 0.00% | – |
| Q3 2016 | $492,000 | +34.1% | 111,405 | -14.0% | 0.00% | – |
| Q2 2016 | $367,000 | +51.7% | 129,571 | +52.6% | 0.00% | – |
| Q1 2016 | $242,000 | -59.2% | 84,919 | +47.9% | 0.00% | -100.0% |
| Q4 2015 | $593,000 | -19.2% | 57,410 | -10.7% | 0.00% | 0.0% |
| Q3 2015 | $734,000 | -73.2% | 64,321 | -64.9% | 0.00% | -66.7% |
| Q2 2015 | $2,737,000 | +324.3% | 183,309 | +156.5% | 0.00% | +200.0% |
| Q1 2015 | $645,000 | -21.2% | 71,455 | +6.1% | 0.00% | 0.0% |
| Q4 2014 | $819,000 | +23.0% | 67,353 | -1.2% | 0.00% | 0.0% |
| Q3 2014 | $666,000 | -2.5% | 68,172 | +27.5% | 0.00% | 0.0% |
| Q2 2014 | $683,000 | -53.8% | 53,488 | -61.7% | 0.00% | 0.0% |
| Q1 2014 | $1,479,000 | +41.7% | 139,758 | +1.8% | 0.00% | 0.0% |
| Q4 2013 | $1,044,000 | +944.0% | 137,283 | +897.0% | 0.00% | – |
| Q3 2013 | $100,000 | -9.9% | 13,769 | -80.8% | 0.00% | – |
| Q2 2013 | $111,000 | +270.0% | 71,725 | +182.4% | 0.00% | – |
| Q1 2013 | $30,000 | – | 25,402 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DG Capital Management, LLC | 1,186,726 | $4,076,000 | 2.45% |
| Sarissa Capital Management LP | 4,861,000 | $16,697,000 | 1.97% |
| Ghost Tree Capital, LLC | 1,950,000 | $6,698,000 | 1.94% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,525,857 | $8,676,000 | 1.14% |
| Eversept Partners, LP | 1,143,211 | $3,926,930 | 0.87% |
| DAFNA Capital Management LLC | 749,051 | $2,573,000 | 0.84% |
| KNOTT DAVID M | 397,361 | $1,365,000 | 0.80% |
| Parkman Healthcare Partners LLC | 800,740 | $2,751,000 | 0.73% |
| ACUTA CAPITAL PARTNERS, LLC | 660,000 | $2,267,000 | 0.62% |
| Formidable Asset Management, LLC | 578,200 | $1,949,000 | 0.57% |